Sep 1, 2026 07:30AM
Sep 1, 2026 07:30AM
Aug 5, 2026 08:00AM
Aug 3, 2026 04:01PM
Jul 27, 2026 04:01PM
Jul 13, 2026 07:30AM
Jul 13, 2026 07:30AM Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
Jun 30, 2026 08:01AM
Jun 30, 2026 08:00AM
May 28, 2026 04:01PM
May 7, 2026 04:01PM
Apr 30, 2026 04:01PM
Apr 8, 2026 04:01PM
Apr 8, 2026 09:15AM The Credibility Filter Wall Street Uses to Sort Biotech Winners
Apr 7, 2026 04:01PM
Apr 7, 2026 04:01PM
Mar 20, 2026 06:58AM
Mar 4, 2026 05:05PM
Feb 24, 2026 04:01PM
Feb 11, 2026 07:30AM
Feb 11, 2026 07:30AM Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)
Feb 4, 2026 04:01PM
Jan 12, 2026 07:45AM
Jan 11, 2026 02:00PM
Jan 11, 2026 02:00PM
Jan 5, 2026 04:34AM
Dec 5, 2025 09:01AM
Dec 5, 2025 09:00AM Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 America
Dec 5, 2025 09:00AM
Dec 1, 2025 07:31AM
Dec 1, 2025 07:30AM
Nov 4, 2025 04:01PM
Oct 20, 2025 07:30AM
Oct 13, 2025 01:34PM
Oct 9, 2025 04:31PM Biogen and Stoke present 3-year zorevunersen data for Dravet syndrome
Oct 9, 2025 04:30PM
Oct 9, 2025 04:30PM
Sep 2, 2025 07:03AM
Sep 2, 2025 07:01AM
Sep 2, 2025 07:00AM
Sep 2, 2025 07:00AM
Aug 25, 2025 07:00AM Stoke Therapeutics and Biogen to present zorevunersen data at epilepsy congress
Aug 25, 2025 07:00AM
Aug 25, 2025 07:00AM
Aug 18, 2025 05:11AM
Aug 12, 2025 04:01PM
Aug 11, 2025 07:00AM
Aug 11, 2025 07:00AM
Aug 11, 2025 07:00AM Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
Aug 11, 2025 07:00AM

329,929 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All